Generic Name: glycopyrrolate
Brand Name: Cuvposa
Manufacturer: MEDEXUS Pharmaceuticals, Inc.
Indications: chronic severe drooling, neurologic (pediatric)
Manufacturer Requested Reimbursement Criteria1: Cuvposa (glycopyrrolate) is indicated to reduce chronic severe drooling in patients aged 3-18 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy).
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input posted||April 11, 2019|
|Patient group input closed||June 03, 2019|
- No patient input submission received
|Submission received||May 31, 2019|
|Submission accepted for review||June 14, 2019|
|Review initiated||June 24, 2019|
|Draft CADTH review report(s) sent to sponsor||September 16, 2019|
|Comments from sponsor on draft CADTH review report(s) received||September 25, 2019|
|CADTH review team's comments on draft CADTH review report(s) sent to sponsor||November 08, 2019|
|Canadian Drug Expert Committee (CDEC) meeting||November 20, 2019|
|CDEC recommendation sent to sponsor and drug plans||December 02, 2019|
December 04, 2019